Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients.

ABSTRACT:

Background/aims

A switch to systemic therapy, such as sorafenib, should be considered for hepatocellular carcinoma (HCC) patients refractory to transarterial chemoembolization (TACE). On the other hand, treatment changes are difficult if the liver function worsens to Child-Pugh B or C. Therefore, predicting the risk factors for non-responsiveness to TACE and deteriorating liver function may be helpful.

Methods

Newly diagnosed Child-Pugh A HCC patients who underwent TACE from January 2012 to June 2018 were included. After 1 year, this study evaluated whether there was a treatment response to TACE and whether the Child-Pugh class had worsened.

Results

Among 121 patients, 65 were refractory and 56 responded to TACE. In multivariable logistic regression analysis, the tumo

SUBMITTER: Park KH 

PROVIDER: S-EPMC12285829 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature